Figure 3From: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo (A) Percentage of CD16 + CD56+ lymphocytes (NK cells) in healthy controls and in patients with melanoma or vitiligo, (B) Percentage of CD16 + CD56+ overall white blood cells (NK cells) in healthy controls and in patients with melanoma or vitiligo, (C) Percentage of CD16+ overall white blood cells in healthy controls and in patients with melanoma or vitiligo, (D) Percentage of CD89+ overall white blood cells in healthy controls and in patients with melanoma or vitiligo. Red squares represent melanoma patients with metastatic disease, while brighter red squares with borders represent melanoma patients without metastases.Back to article page